|
|
Vaccine Detail
|
Contusugene ladenovec |
| Vaccine Information |
- Vaccine Name: Contusugene ladenovec
- Target Pathogen: Cancer
- Target Disease: Cancer
- Product Name: Ad-p53; Ad5CMV-p53 Gene
- Vaccine Ontology ID: VO_0007594
- Type: Other
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- Antigen: p53
- human TP53 (P53)
gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
- Description: A replication-defective adenoviral-CMV vector that encodes a wild-type p53 gene. Ad5CMV-p53 induces tumor cells that have been transfected with the vector to produce wild-type p53, a tumor suppressor gene that is deleted or mutated in a significant number of cancers. In transfected tumor cells, the wild-type p-53 gene product exerts an antitumor effect by blocking cell cycle progression at the G1/S regulation point, activating DNA repair proteins in the presence of DNA damage, and initiating apoptosis when DNA damage is irreparable. (NCI04) (NCIT_C2471).
|
| Host Response |
|
Baboon Response
- Description: A clinical trial on this vaccine is reported with the ClinicalTrials.gov Identifier: NCT03544723 (Clinical trial NCT03544723).
|
| References |
Clinical trial NCT03544723: Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors [https://clinicaltrials.gov/ct2/show/NCT03544723]
NCIT_C2471: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2471]
|
|
